BioXcel股价在完成关键第三阶段试验后飙升

英为财情

2025/08/01

Investing.com -- BioXcel Therapeutics Inc (NASDAQ:BTAI)股价在宣布完成其IGALMI®(右美托咪啶)关键性第三阶段SERENITY居家临床试验后跳升23.7%。这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。预计本月将发布...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556816217"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556816217\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556816217?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-01 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556816217","market":"sh","top_or_hot":-1,"title":"BioXcel股价在完成关键第三阶段试验后飙升","media":"英为财情","content":"<div>\n<p>Investing.com --  BioXcel Therapeutics Inc  (NASDAQ:BTAI)股价在宣布完成其IGALMI®(右美托咪啶)关键性第三阶段SERENITY居家临床试验后跳升23.7%。\n这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。预计本月将发布...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2915677\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioXcel股价在完成关键第三阶段试验后飙升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioXcel股价在完成关键第三阶段试验后飙升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-01 21:02 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2915677><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com --  BioXcel Therapeutics Inc  (NASDAQ:BTAI)股价在宣布完成其IGALMI®(右美托咪啶)关键性第三阶段SERENITY居家临床试验后跳升23.7%。\n这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。预计本月将发布...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2915677\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BTAI","symbol_name":"Bioxcel Therapeutics Inc.","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2915677","article_id":"2556816217","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2915677","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2556816217","pubTimestamp":1754053320,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com --  BioXcel Therapeutics Inc  股价在宣布完成其IGALMI关键性第三阶段SERENITY居家临床试验后跳升23.7%。这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。这项第三阶段试验在全国22个站点招募了200多名患者,双相情感障碍和精神分裂症患者分布均衡。该研究结果旨在支持BioXcel计划中的补充新药申请,以潜在地扩大IGALMI在门诊环境中的使用标签。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BTAI":"Bioxcel Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"BioXcel stock surges after completing key Phase 3 trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTAI":1},"content_text":"Investing.com --  BioXcel Therapeutics Inc  (NASDAQ:BTAI)股价在宣布完成其IGALMI®(右美托咪啶)关键性第三阶段SERENITY居家临床试验后跳升23.7%。\n这家利用人工智能开发神经科学药物的生物制药公司报告称,该研究已完成最后一位患者访视,该研究评估IGALMI用于治疗居家环境中与双相情感障碍或精神分裂症相关的激动状态。预计本月将发布该试验的顶线数据。\n这项第三阶段试验在全国22个站点招募了200多名患者,双相情感障碍和精神分裂症患者分布均衡。这项双盲、安慰剂对照研究旨在评估120微克剂量BXCL501用于急性激动状态治疗的安全性。\n该研究结果旨在支持BioXcel计划中的补充新药申请(sNDA),以潜在地扩大IGALMI在门诊环境中的使用标签。\n\"这标志着我们努力为数百万经历与双相情感障碍或精神分裂症相关激动状态的个体提供急需的居家治疗选择的重要里程碑,\"BioXcel Therapeutics首席执行官Vimal Mehta表示。\n据该公司称,美国每年约有2300万次在家中发生的与双相情感障碍或精神分裂症相关的激动发作,目前尚无FDA批准的疗法可用于在这种环境中进行急性治疗。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}